thesis-toulmin
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q35328550-338ECC93-2757-405D-A16D-E0218120FBC3
Q35328550-338ECC93-2757-405D-A16D-E0218120FBC3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35328550-338ECC93-2757-405D-A16D-E0218120FBC3
Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.
P2860
Q35328550-338ECC93-2757-405D-A16D-E0218120FBC3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35328550-338ECC93-2757-405D-A16D-E0218120FBC3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
9c6974ea2c28391eaf4a05f0a2c9415400579a8e
P2860
Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.